Background. World Health Organization guidelines for prevention of mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) recommend administration of zidovudine and single-dose nevirapine (NVP) for HIV-1-infected women who are not receiving treatment for their own health or if complex regimens are not available. This study assessed antiretroviral resistance patterns among HIV-infected women and infants receiving single-dose NVP in Thailand, where the predominant circulating HIV-1 strains are CRF01_AE recombinants and where the minority are subtype B.
of human immunodeficiency virus type 1 (HIV-1) include highly active antiretroviral therapy for eligible women. For women who are not otherwise eligible for treatment or who reside in settings where more-complex regimens cannot be delivered, the guidelines recommend zidovudine, starting at 28 weeks gestation; single-dose nevirapine and zidovudine-lamivudine dur-
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ing labor; and zidovudine-lamivudine after delivery [1] . Thailand's Ministry of Public Health guidelines for PMTCT of HIV-1 infection were revised in 2006, in accordance with WHO recommendations [2] , and include a 7-day postpartum regimen of zidovudine-lamivudine after receipt of single-dose nevirapine, given in hopes of reducing the development of new nevirapine-associated mutations. Despite a number of studies that have documented the emergence of antiretroviral resistance in mother-infant pairs after exposure to regimens for PMTCT of HIV-1 infection, most studies have involved women who were infected with HIV-1 subtype C [3] . Limited data are available on the rates of drug resistance to HIV-1 in mother-infant pairs primarily infected with HIV-1 recombinant strain CRF01_AE (formerly known as subtype E) [4] . Studies of new nevirapine-associated mutations are difficult to compare, because rates vary by stage of maternal HIV-1 disease, amount of nevirapine exposure, number of maternal samples tested, timing of samples, infecting viral strain, and laboratory method [3] [4] [5] [6] .
The objectives of this study were to assess the emergence of resistance mutations in women and infants who were primarily infected with HIV-1 subtype CRF01_AE and who received short-course zidovudine beginning at 34 weeks' gestation (then the standard of care in Thailand) and single-dose nevirapine to reduce maternal-to-infant HIV-1 transmission. We measured the proportion of HIV-1-infected women and infants who developed and retained genotypic resistance markers to nevirapine or zidovudine, and we determined which variables were associated with the development of nevirapine-resistance mutations.
METHODS
Design and study population. HIV-1-infected women were enrolled in this study at 2 urban medical centers located in Bangkok, Thailand. Women were excluded if they had ever received antiretrovirals or HIV-1 immunotherapy (other than zidovudine for perinatal prophylaxis during the current pregnancy) or were enrolled in other HIV-1 studies.
All women who agreed to participate in the study reported to the study center during labor and were administered zidovudine and a single 200-mg nevirapine tablet. If women did not deliver within 48 h, a second 200-mg dose of nevirapine was administered. Women in false labor were administered an additional dose of nevirapine when they were readmitted with active labor.
A single infant dose of nevirapine suspension (2 mg/kg) was given orally 48-72 h after birth. Infants were given their doses immediately after birth if no maternal nevirapine dose had been given or if the maternal dose had been administered !1 h before delivery.
In addition to the nevirapine regimen, women received the standard perinatal prophylaxis regimen, which consisted of oral zidovudine (300 mg twice daily) from week 34 of gestation until the onset of labor, followed by oral zidovudine (300 mg), which was given at the onset of labor and then every 3 h until delivery. The infant zidovudine regimen consisted of oral zidovudine syrup (2 mg/kg) given every 6 h for 4 weeks after birth. At the time of our study, a postpartum 7-day course of zidovudine-lamivudine treatment had not yet been recommended for women, and no women received this regimen. The study protocol was reviewed and approved by the Thailand Ministry of Public Health Ethical Review Committee for Human Subjects Research, the Mahidol University Institutional Review Board, and the Centers for Disease Control and Prevention Institutional Review Board. All women provided written informed consent for participation.
Clinical and laboratory evaluations. A maternal history and physical examination were performed at baseline during antenatal care, during hospitalization for delivery, and at 1 and 2 months after delivery. Blood samples were collected from mothers at baseline, delivery, 1 week, 1 month, and 4 months for laboratory testing. CD4 cell counts were determined at delivery only. Quantitative plasma HIV-1 RNA tests were done for all women at baseline (before they had received zidovudine), delivery (before or shortly after nevirapine administration), and 1 month after delivery; for a subset of women whose delivery HIV-1 RNA sample had been obtained before the administration of nevirapine, the HIV-1 RNA level was also determined at 1 week and 4 months after delivery. Maternal samples for resistance typing were available at the same time points as samples collected for HIV-1 RNA. Month-1 postpartum samples were tested for resistance first. Other samples were tested only if a mutation was found.
Blood samples were obtained from infants р48 h after birth and at 1, 2, and 4 months of age. Qualitative HIV-1 DNA and RNA and quantitative RNA polymerase chain reaction (PCR) tests were performed with use of specimens obtained at birth and at months 1, 2, and 4. Resistance tests were performed for all available samples from HIV-1-infected infants at months 1 and 2 of age.
Laboratory methods. The complete blood cell count was determined in real time using a QBC instrument (Becton Dickinson). Hepatitis B surface antigen (HBsAg) testing was done at the participating hospital laboratories as part of routine antenatal care. CD4 cell testing was performed within 24 h of delivery using FACScan 2-color flow cytometry (Becton Dickinson) [7] . Samples were then separated into plasma and peripheral blood mononuclear cell pellets and were frozen at Ϫ70ЊC within 4-6 h. For qualitative PCR assays for HIV-1 DNA and RNA, we used the Roche Amplicor HIV-1, version 1.0 or 1.5, and the NucliSens HIV-1 QL (bioMérieux).
Plasma viral loads were determined within days to a few weeks after the blood samples had been obtained using the Amplicor Monitor HIV-1, version 1.5 (Roche Molecular Systems). The range of quantitation was 400-750,000 copies/mL. Specimens with viral loads that were detectable but not quantifiable at levels !400 copies/mL and those that with undetectable viral loads were assigned values of 200 copies/mL and 0 copies/mL, respectively. Specimens with viral loads 1750,000 copies/mL were diluted, and a dilution factor was applied to obtain the actual value. Determination of resistance mutations was performed р2 years after obtainment of samples using the TruGene HIV-1 genotyping assay (Bayer HealthCare) and OpenGene software (Guideline 10.0 library). HIV-1 serotyping was conducted with an enzyme immunoassay that used V3 loop peptides specific for HIV-1 subtypes B, B (Thai B), and CRF01_AE [8] . Laboratory testing was performed at the Thailand Ministry of Public Health-US CDC Collaboration laboratory (Nonthaburi, Thailand).
Definition of HIV-1 infection in infants.
Infants with at least 1 positive qualitative DNA PCR result and 1 positive qualitative RNA PCR result were classified as HIV-1 infected. Infants were classified as uninfected if they had at least 2 HIV-1 negative DNA PCR results (one of which had to be obtained at or after 2 months of age) and no positive RNA PCR results. Infants not meeting these conditions were classified as indeterminate.
Statistical analysis. Statistical analysis was performed using SAS software, version 8 (SAS Institute). The x 2 test or Fisher's exact test was used to compare categorical variables. Student's t test or the Wilcoxon test was used to compare differences for continuous variables. Continuous variables were dichotomized at the median or at levels used frequently by other related studies. For categorical variables, associations between independent variables and the development of mutations associated with nevirapine resistance were estimated using odds ratios (OR) and 95% confidence intervals (CIs). Logistic regression models assessed maternal and infant characteristics as predictors of resistance. Univariate analyses were performed for all variables potentially associated with nevirapine resistance. A multivariate model was created that included all reported variables found to be significant ( ). Adjusted ORs and P р .1 95% CIs were estimated in the final logistic model on the basis of a backwards selection criteria dropping insignificant variables ( ). P 1 .05
RESULTS

Study Population Characteristics
Baseline characteristics. From February 2001 through January 2003, a total of 228 HIV-1-infected women were enrolled in the study; 8 of these women elected not to continue the protocol or did not deliver their children at the study hospitals. The 220 women delivered 223 live-born infants.
The median age of women at entry was 26 years (range, 18-48 years), and the median gestational age was 32 weeks (range, 11-34 weeks). Among 223 infants, 174 (78%) were 137 weeks gestational age (median, 39 weeks); the median birth weight was 3000 g; 26 infants (12%) weighed !2500 g.
Delivery maternal median CD4 cell count was 378 cells/mm 3 ; 37 women (17%) had CD4 cell counts !200 cells/mm 3 . The median viral load for mothers at the antenatal care baseline visit-prior to the initiation of zidovudine treatment-was 21,890 copies/mL (range, 200-1,500,000 copies/mL). At delivery, the median viral load for mothers was 3214 copies/mL (range, 200-376,871 copies/mL); 39 mothers (18%) had a viral load !400 copies/mL.
Use of zidovudine and nevirapine. One hundred ninetyeight women (90%) had received at least 2 weeks of zidovudine treatment prior to delivery, and 124 women (56%) had received at least 4 weeks of zidovudine treatment prior to delivery. Five women delivered their children before they had started antenatal zidovudine treatment; only 1 woman delivered without having received antenatal or intrapartum zidovudine treatment. Twelve mothers (5%) missed their intrapartum nevirapine dose during labor. None of the women in the study received any antiretroviral drugs during the postpartum follow-up period.
All 223 infants (100%) received nevirapine. All infants initiated zidovudine treatment р24 h after birth, and 217 (97%) completed the prescribed 1 month of therapy.
Antiretroviral Resistance
Results for mothers. Of the 208 women who received singledose nevirapine during labor and delivery, plasma samples were available from 204 (98%) for resistance testing at 4-6 weeks after delivery. All available samples were analyzed, and 190 (93%) maternal samples were successfully sequenced. Most women (82%) had no detectable mutations. Thirty-four women (18%) had у1 mutation associated with nevirapine resistance (table 1); none of the women had mutations associated with zidovudine resistance. The most common nevirapine mutation was K103N, which was found alone ( ) n p 12 or in combination with other nevirapine mutations ( ). n p 5 Three women (2%) had an M41L mutation associated with zidovudine resistance but no mutations associated with nevirapine resistance. Median viral loads at baseline and delivery were significantly higher ( ) in women who developed P ! .01 resistance associated with nevirapine than among those who did not.
In the 34 women with mutations associated with nevirapine resistance at 1 month after delivery, no mutations were found in any baseline or delivery samples. One of these 34 women received 2 doses of nevirapine prior to delivery due to false labor. Fifteen women had samples available to examine the persistence of nevirapine resistance through 4 months after delivery; 2 women still had resistance at this time point. One woman had K101Q and K103N mutations at 7 days after delivery. At 1 month after delivery, only the K101Q mutation was detected, but at 4 months, K101Q and K103N mutations were both detected, indicating a likely persistence of both mutations to 4 months after delivery. The other woman had no resistance mutations noted 7 days after delivery, but Y181C and G190A mutations were detected 1 month after delivery, and the Y181C mutation was still detectable 4 months after delivery. Two of the 34 women with nevirapine-associated mutations had HIV-1-infected infants, but no nevirapine or zidovudine mutations were detected in the infants.
To determine what factors were associated with nevirapine resistance mutations in the mothers, viral load at baseline and delivery, CD4 cell count at delivery, and other factors were compared for women with versus women without nevirapineassociated mutations (table 2) . In a bivariate analysis, the development of mutations associated with nevirapine resistance was highest among women with delivery viral loads (before or after receipt of nevirapine) of 150,000 copies/mL (OR, 6.89; 95% CI, 1.97-24.12; for linear trend) and lower CD4 P p .002 cell counts at delivery (OR, 2.44; 95% CI, 0.88-6.77; P p ). A positive HBsAg result during antenatal care was also .034 associated with the presence of nevirapine-associated resistance mutations (OR, 5.1; 95% CI, 1.39-18.8:
). HIV-1 sub-P p .007 type was significantly associated with the presence of nevirapine-associated resistance mutations. Mutations were more prevalent in women infected with subtype B than in those infected with subtype CRF01_AE (OR, 3.05; 95% CI, 1.02-
9.12;
). Primagravida women were less likely to de-P p .038 velop resistance than were multigravida women (OR, 0.38; 95% CI, 0.16-0.89;
). Factors included in a multiple logistic P p .02 regression model were CD4 cell count, viral load, HIV-1 subtype, HBsAg, age, and parity; only delivery viral load and HIV-1 subtype remained independent predictors ( ) (table 2) . P ! .05 Results for infants. Of the 223 live-born infants, 10 were HIV-1 infected, 205 were HIV-1 uninfected, 6 were lost to follow-up, and 2 died before the diagnosis of HIV-1 infection could be confirmed. All infants who died or were lost to followup had at least 1 negative HIV-1 test result and no positive test results. Seven (70%) of 10 HIV-1-infected infants had a positive HIV-1 DNA or RNA PCR test result at birth.
Samples obtained from all 10 HIV-1-infected infants at 2 months of age were successfully sequenced. At this time point, 2 infants (20%) had mutations associated with nevirapine resistance (A98S/V179D for one and K103N for the other). These 2 infants received diagnoses of HIV-1 infection at 1 and 2 months of age. At 4 months of age, the K103N mutation persisted in 1 infant, but the A98S/V179D mutation was not detected in the other. A third infant had the M41L mutation, which is associated with zidovudine resistance, at 4 months of age but not at 2 months of age. No nevirapine-or zidovudineresistance mutations were detected in the mothers of these 10 infants. Median viral loads of HIV-1-infected infants were 2,053,790 copies/mL and 732,908 copies/mL at 2 and 4 months of age, respectively, and did not significantly differ for infants with versus infants without resistance. Analysis of variables possibly associated with development of antiretroviral resistance in infants did not identify any significant factors (data not shown).
DISCUSSION
The proportion of women with у1 mutation associated with nevirapine resistance (18%) in this study of HIV-1-positive women who were primarily infected with CRF01_AE subtype was less than what has been observed in most studies. In other studies, nevirapine-associated mutations have been detected in 15%-69% of women who are administered single-dose nevirapine for PMTCT as monotherapy or in combination with other antenatal HIV-1 prophylaxis, with most studies showing a resistance prevalence of ∼40% [9] [10] [11] [12] [13] [14] . It is possible that the lower frequency in our study may be explained by differences in viral strains.
Several studies suggest that it is relevant to consider the infecting viral strain when analyzing HIV-1 mutations associated with drug resistance. In a study of samples from Malawi and Uganda, nevirapine-associated resistant mutations were more common among women infected with subtype C (69%) than in those infected with subtype D (36%) or A (19%) [3] . In our study, 16% and 38% of CRF01_AE-and B-infected women, respectively, developed new mutations associated with nevirapine resistance. This is the first report of such an association in Thailand. A limitation of this conclusion is that serologic subtyping methods may underestimate HIV-1 diversity by not detecting recombinant or novel strains. Nevertheless, the distribution of CRF01_AE and B subtypes among the women for whom the subtype could be determined reflects the known distribution of CRF01_AE in Thai populations of similar risk [15] . Because CRF01_AE is a recombinant subtype, with large portions of the genome derived from subtype A, these data suggest that viral strains containing subtype A or CRF01_AE genes may be less susceptible to the induction of nevirapine resistance than subtype B viruses. Alternatively, some mutations defined as likely to be associated with nevirapine resistance in subtype B backgrounds may not be associated with resistance in other subtypes or strains and may reflect natural polymorphisms. With use of the WHO's definition of transmitted polymorphisms, some mutations (e.g., A98S, V108I, and K101Q in reverse transcriptase) considered to be associated with nevirapine resistance in our study and other studies may reflect natural polymorphisms [16] . However, in our study, the 3 women and 1 infant who had these polymorphisms in post-nevirapine samples did not have them in pre-nevirapine (or maternal) samples; therefore we considered it likely that these polymorphisms were nevirapine induced.
We found that a positive antenatal HBsAg result was associated with the presence of nevirapine-associated resistance mutations in the bivariate analysis; however, this association was not significant in the final model. Biological explanations for this observation could not be fully examined, because hepatitis antigen and antibody tests were not performed for all women during antenatal care.
Several additional reasons could also explain the lower frequency of resistance mutations in our study versus some other studies, including maternal viral load, number of nevirapine doses, nevirapine plasma concentrations, timing of sampling, receipt of other antiretrovirals, and type of assay.
Advanced maternal disease has been associated with nevirapine mutations, and the development of maternal nevirapine resistance has been shown to be associated with a higher baseline viral load [6] . In our study, we found an association between high viral load at delivery and the development of mutations, although the median viral load in our population was lower than in other studies [6] .
Differences in testing methods can also influence the ability to detect mutations in the HIV-1 genome. In our study, the TruGene sequence-based assay was used, whereas some other studies have used different methods. However, this is not likely to be a significant factor, because most widely used commercial or in-house sequence-based assays have similar sensitivities and detect populations that constitute 120% of the total viral population. New ultrasensitive technologies based on real-time PCR or other methods have recently been developed; these can detect nevirapine-associated resistance mutations in 160% of nevirapine-treated women [17] [18] [19] [20] . However, it is likely that, in our study and in other studies that have used standard assays, the prevalence of nevirapine-associated resistance mutations is significantly underestimated.
Only 2 of the 10 HIV-1-infected infants developed nevirapine-associated mutations. This number is consistent with some studies in which infants received single-dose nevirapine plus other antiretrovirals [12] but is lower than most studies that evaluated single-dose nevirapine alone or in combination with zidovudine [21, 22] . To our knowledge, there is only one other study from Thailand, and that study reported a much lower rate (4/50, 8%) in non-breast-fed HIV-1-infected infants exposed to a maternal and neonatal dose of nevirapine and to 1-6 weeks of neonatal zidovudine for PMTCT [23] . The small number of HIV-1-infected infants in our study made it difficult to analyze factors associated with the development of resistance mutations in the infants.
In summary, this study lends increased understanding to the development of nevirapine resistance mutations in a Thai population. More data are needed to understand the correlates of emergence of resistance mutations, and to support increased efforts of Thailand and other Southeast Asian countries to provide combination regimens that may reduce the development of new nevirapine resistance mutations.
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